New cell-based therapy aims to protect hearing during cochlear implant surgery
NCT ID NCT06545175
First seen Feb 13, 2026 · Last updated May 14, 2026 · Updated 15 times
Summary
This early-phase trial tests whether a special cell-derived liquid, called VSF1.01, can safely reduce trauma to the inner ear during cochlear implant surgery. Eleven adults with severe hearing loss will receive the treatment directly into the cochlea before the implant is placed. The main goal is to check safety, but researchers will also measure nerve responses, speech understanding, and hearing thresholds.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEARING LOSS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hannover Medical School, Dept. of Otorhinolaryngology
RECRUITINGHanover, 30625, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.